|
|
News Breaks
|
November 18, 2009
|
| 07:04 EDT |  | ALNY |
| theflyonthewall.com: | Alnylam Pharmaceuticals new preclinical ALN-VSP data | | Alnylam Pharmaceuticals announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass. ALN-VSP is an RNAi therapeutic currently in a Phase I clinical trial for the treatment of liver cancers, including hepatocellular carcinoma and other solid tumors with liver involvement. The new data demonstrated robust anti-tumor activity in orthotopic liver tumor models comprised of both HCC- and colorectal cancer-derived cell lines. ALN-VSP was also shown to act on disseminated tumors outside of the liver. Further, in addition to anti-proliferative effects, studies showed that ALN-VSP exerts a potent anti-angiogenic effect on tumors. :theflyonthewall.com |
|
|
News For ALNY From The Last 14 Days Check below for free stories on ALNY the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 08:06 EDT | | ALNY |
| theflyonthewall.com: | Alnylam scientists discovery novel method for monitoring RNAi activity | | Alnylam Pharmaceuticals announced that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics. This new method, called “circulating extracellular RNA detection," allows quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid. Alnylam intends to enable use of the new technology in academic research and license industry to deploy the technology. :theflyonthewall.com |
|
|
January 30, 2012
|
| 08:07 EDT | | ALNY |
| theflyonthewall.com: | Alnylam gets patent for second generation LNP for delivery of RNAi therapeutics |
 Subscribe for More Information :theflyonthewall.com |
|
|
|
|
|
